Xtacy Therapeutics Corp.
Pegasus Mercantile Inc. is an incubator, venture capital firm specializing in incubation, startup and early stage. The firm seeks to invest in the public and private sectors that focus on preventative health, wellness issues, related consumer products, biotechnology, specific areas of pain, Psychedelic, depression, mental illness health and medicine sectors. By investing in pioneering techniques … Read more
Xtacy Therapeutics Corp. (XTCYF) - Total Liabilities
Latest total liabilities as of June 2025: $737.94K USD
Based on the latest financial reports, Xtacy Therapeutics Corp. (XTCYF) has total liabilities worth $737.94K USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Xtacy Therapeutics Corp. - Total Liabilities Trend (2020–2024)
This chart illustrates how Xtacy Therapeutics Corp.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Xtacy Therapeutics Corp. Competitors by Total Liabilities
The table below lists competitors of Xtacy Therapeutics Corp. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CLAS OHLSON -B-
BE:OHCB
|
Germany | €4.16 Billion |
|
First Berlin Bancorp Inc.
OTCMKTS:FTFI
|
USA | $593.29 Million |
|
PetVivo Holdings Inc. Warrant
NASDAQ:PETVW
|
USA | $1.08 Million |
|
Jaba I Inversiones Inmobiliarias Socimi SA
MC:YABA
|
Spain | €11.98 Million |
|
Sensor Technologies Corp
PINK:MOOIF
|
USA | $1.12 Million |
|
Origen Resources Inc
PINK:OGGNF
|
USA | $676.79K |
|
Protagenic Therapeutics
NASDAQ:PTIX
|
USA | $6.82 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Xtacy Therapeutics Corp.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.00 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xtacy Therapeutics Corp.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xtacy Therapeutics Corp. (2020–2024)
The table below shows the annual total liabilities of Xtacy Therapeutics Corp. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-09-30 | $882.11K | +25.45% |
| 2023-09-30 | $703.15K | -5.81% |
| 2022-09-30 | $746.49K | +37.51% |
| 2021-09-30 | $542.85K | +105.12% |
| 2020-09-30 | $264.65K | -- |